JNJ issues 2017 guidance, reports full-year Darzalex sales

On Tuesday, Johnson & Johnson (NYSE:JNJ) reported mixed 4Q16 earnings and issued full-year 2017 guidance that fell short of analysts' consensus. The company also reported strong sales of

Read the full 287 word article

User Sign In